Amgen’s Mvasi (bevacizumab-awwb) biosimilar exited 2020 as the leading bevacizumab product in the US by market share, ahead of Roche’s Avastin reference brand, with a 48% holding achieved less than 18 months after launch.
The California-based biotech remains optimistic about its US and international prospects for Mvasi, which generated revenues of $656m in the US last year and $798m overall
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?